Sumitomo Pharma America (formerly Sunvion) has said that its ulotaront (SEP-363856), a novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, was unable to ...

Sumitomo Dainippon Pharma Co (JP:4506) has released an update. Sumitomo Pharma Co. has concluded its early retirement program aimed at business restructuring, receiving 604 applications against a ...

A sweetened offer from Sumitomo Pharma has convinced endocrinology specialist Myovant to agree to a takeover, after its first was rejected. Sumitomo and its subsidiary Sumitovant Biopharma ...

Sumitomo Dainippon Pharma Co (JP:4506) has released an update. Sumitomo Pharma Co. has reported significant finance costs due to foreign ...

Sumitomo Dainippon Pharma Co ( (DNPUF) ) has released its Q2 earnings. Here is a breakdown of the information Sumitomo Dainippon Pharma Co ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

Japan stocks were higher after the close on Tuesday, as gains in the Glass, Transportation Equipment and Banking sectors led ...

Sumitomo Pharma was founded in 1897 and operates in Osaka, Japan. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100). This industry belongs ...

On Monday, Sumitomo Pharma's (4506:JP) (OTC: DNPUF) stock rating was downgraded by Citi from Neutral to Sell. The new price target is set at JPY460.00. The decision for the downgrade was influenced by ...

Sumitomo Dainippon Pharma Co (JP:4506) has released an update. Sumitomo Pharma Co. has reported significant finance costs due to foreign exchange losses totaling 21,479 million yen for the first ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...